Curasight has reported its Q3/22 quarterly report. In terms of the P&L, there is nothing to report on since it is an early-stage biotech company with zero revenue. Curasight is executing on its strategy and just recently added two more indications to its pipeline: Neuroendocrine tumours and head and neck cancer. We have long commented on this subject and refer readers who want to know more about Curasigt’s expanded strategy to our previous comments.
Outcome: Continuing on the same path
Nothing to report in terms of numbers other than that the company had a cash position of DKK 56m which we believe is more than enough to continue to execute on its strategy long into 2023.
Få vores øvrige investeringsnyheder direkte i din indbakke. Tilmeld dig vores gratis daglige nyhedsbrev her:
Tilmeld dig vores gratis nyhedsbrev om
Dagens Nyheder Investering
Vær et skridt foran. Få de vigtigste investeringsnyheder direkte i indbakken. Det er gratis og udkommer hver dag.